

Supplemental Material

Search strategy2

Supplemental Table 1. Search details.....3

Quality Assessment4

Supplemental Figure 1. Risk of bias in randomized trials according to the Cochrane risk-of-bias tool for randomized trials (RoB-2).4

Main Results5

Supplemental Figure 2. Forest plots representing the risk of all-cause mortality after abbreviated DAPT vs. conventional DAPT in HBR vs. non-HBR patients.5

Supplemental Figure 3. Forest plots representing the risk of cardiovascular mortality after 1- and 3-month abbreviated DAPT vs. conventional DAPT.6

Supplemental Figure 4. Forest plots representing the risk of cardiovascular mortality after abbreviated DAPT vs. conventional DAPT in pre-specified subgroups.....6

Supplemental Figure 5. Forest plots representing the risk of cardiovascular mortality after abbreviated DAPT vs. conventional DAPT in HBR vs. non-HBR patients.7

Supplemental Figure 6. Forest plots representing the risk of stroke after 1- and 3-month abbreviated DAPT vs. conventional DAPT.8

Supplemental Figure 7. Forest plots representing the risk of stroke after abbreviated DAPT vs. conventional DAPT in pre-specified subgroups.....10

Supplemental Figure 8. Forest plots representing the risk of stroke after abbreviated DAPT vs. conventional DAPT in HBR vs. non-HBR patients.11

Supplemental Figure 9. Forest plots representing the risk of non-fatal MI after 1- and 3-month abbreviated DAPT vs. conventional DAPT.....12

Supplemental Figure 10. Forest plots representing the risk of non-fatal MI after abbreviated DAPT vs. conventional DAPT in pre-specified subgroups.13

Supplemental Figure 11. Forest plots representing the risk of non-fatal MI after abbreviated DAPT vs. conventional DAPT in HBR vs. non-HBR patients.14

.....14

Supplemental Figure 12. Forest plots representing the risk of any revascularization after 1- and 3-month abbreviated DAPT vs. conventional DAPT.15

Supplemental Figure 13. Forest plots representing the risk any revascularization after abbreviated DAPT vs. conventional DAPT in pre-specified subgroups.....16

Supplemental Figure 14. Forest plots representing the risk of any revascularization after abbreviated DAPT vs. conventional DAPT in HBR vs. non-HBR patients.17

Supplemental Figure 16. Forest plots representing the risk target vessel revascularization after abbreviated DAPT vs. conventional DAPT in pre-specified subgroups.....19

Supplemental Figure 17. Forest plots representing the risk of target vessel revascularization after abbreviated DAPT vs. conventional DAPT in HBR vs. non-HBR patients.20

Supplemental Figure 18. Forest plots representing the risk of in-stent thrombosis after 1- and 3-month abbreviated DAPT vs. conventional DAPT.....21

Supplemental Figure 19. Forest plots representing the risk in-stent thrombosis after abbreviated DAPT vs. conventional DAPT in pre-specified subgroups.....22

Supplemental Figure 20. Forest plots representing the risk of in-stent thrombosis after abbreviated DAPT vs. conventional DAPT in HBR vs. non-HBR patients.23

Supplemental Figure 21. Forest plots representing the risk of MACE after 1- and 3-month abbreviated DAPT vs. conventional DAPT.	24
Supplemental Figure 22. Forest plots representing the risk MACE after abbreviated DAPT vs. conventional DAPT in pre-specified subgroups.....	25
Supplemental Figure 20. Forest plots representing the risk of MACE after abbreviated DAPT vs. conventional DAPT in HBR vs. non-HBR patients.	26
Sensitivity Analysis	27
Supplemental Table 2. Sensitivity analysis using the leave-one-out method for high heterogeneity models ($I^2 > 70\%$) to assess each study's contribution to the pooled estimates.	27
Meta-Regression	31
Supplemental Figure 24. Bubble plot of meta-regression analysis evaluating the age of the overall population as a covariate in all-cause mortality outcome.	31
Supplemental Figure 25. Bubble plot of meta-regression analysis evaluating the male percentage as a covariate in all-cause mortality outcome.....	32
Supplemental Figure 26. Bubble plot of meta-regression analysis evaluating diabetes as a covariate in all-cause mortality outcome.	33
Supplemental Figure 27. Bubble plot of meta-regression analysis evaluating hypertension as a covariate in all-cause mortality outcome.....	34
Publication Bias	35
Supplemental Figure 28. Comparison-adjusted funnel plots for included studies that report all-cause mortality.....	35
Supplemental Figure 29. Comparison-adjusted funnel plots for included studies that report cardiovascular mortality.	36
Supplemental Figure 30. Comparison-adjusted funnel plots for included studies that report stroke. ...	37
Supplemental Figure 31. Comparison-adjusted funnel plots for included studies that report non-fatal MI.	38
Supplemental Figure 32. Comparison-adjusted funnel plots for included studies that report target vessel revascularization.	39
Supplemental Figure 33. Comparison-adjusted funnel plots for included studies that report in-stent restenosis.	40


Search strategy

Supplemental Table 1. Search details

Query	Results (2 Feb 2024)
PubMed	
((PCI[tiab] OR "Percutaneous Coronary Intervention*[tiab] OR “coronary stent*[tiab] OR “drug-eluting stents”[Mesh] OR “drug-eluting stent*[tiab] OR Stent*[tiab] OR “acute coronary syndrome”[Mesh] OR “acute coronary syndrome*[tiab] OR “Coronary artery disease”[Mesh] OR “Coronary artery disease*[tiab] OR “Myocardial Infarction”[Mesh] OR “Myocardial Infarct*[tiab]) AND (DAPT[tiab] OR "Dual Antiplatelet Therapy"[tiab] OR “Dual Antiplatelet Treat*[tiab] OR “Combination Drug Therapy”[tiab] OR SAPT[tiab] OR "Single Antiplatelet Therapy"[tiab] OR “Mono Antiplatelet”[tiab]) AND ("Aspirin"[Mesh] OR "Aspirin"[tiab] OR “Acetylsalicylic Acid”[tiab] OR "Purinergic P2Y Receptor Antagonists"[Mesh] OR "p2y12 inhibitor*[tiab] OR "p2y12 receptor inhibitor*[tiab] OR "p2y12 receptor antagonist*[tiab] OR "Clopidogrel"[Mesh] OR Clopidogrel [tiab] OR Ticagrelor[Mesh] OR Ticagrelor[tiab] OR "Prasugrel Hydrochloride"[Mesh] OR Prasugrel[tiab]) AND (Random*[tiab] OR Trial*[tiab]))	1,435
Scopus	
(TITLE(“dual antiplatelet”) OR TITLE(“single antiplatelet”) OR TITLE-ABS(DAPT) OR TITLE-ABS(SAPT) OR TITLE(p2y12) OR TITLE(prasugrel) OR TITLE(ticagrelor) OR TITLE(clopidogrel) OR TITLE(aspirin)) AND (TITLE(“percutaneous coronary intervention”) OR TITLE(“percutaneous coronary revascularization”) OR TITLE-ABS(PCI) OR TITLE-ABS(“coronary stent*[tiab] OR TITLE-ABS(“drug-eluting stent*)) AND (TITLE-ABS(“random*[tiab] OR TITLE-ABS(“trial*))	2,083
Embase	
('percutaneous coronary intervention'/exp OR 'percutaneous coronary revascularization':ab,ti OR 'acute coronary syndrome':ab,ti OR 'coronary artery disease':ab,ti OR 'myocardial infarc*':ab,ti OR 'stent':ab,ti OR 'drug eluting stent':ab,ti AND 'dapt':ab,ti OR 'dual antiplatelet therapy':ab,ti OR 'drug combination':ab,ti OR 'combination drug therapy':ab,ti OR 'monotherapy':ab,ti OR 'mono-therapy':ab,ti OR 'mono antiplatelet':ab,ti OR 'dual antiplatelet treatment':ab,ti OR 'mono antiplatelet treatment':ab,ti AND 'acetylsalicylic acid':ab,ti OR 'acetylsalicylic acid plus clopidogrel':ab,ti OR 'aspirin':ab,ti AND 'anticoagulant agent':ab,ti OR 'platelet aggregation inhibitor':ab,ti OR 'clopidogrel':ab,ti OR 'plavix':ab,ti OR 'ticagrelor':ab,ti OR 'prasugrel':ab,ti OR 'p2y12 inhibitor':ab,ti OR 'p2y12 receptor antagonist':ab,ti OR 'p2y12 receptor inhibitor':ab,ti AND 'random' OR ‘trial’)	1,375
Total records	4,893
Total records without duplicates	3,184


Quality Assessment

Supplemental Figure 1. Risk of bias in randomized trials according to the Cochrane risk-of-bias tool for randomized trials (RoB-2).




Main Results


Supplemental Figure 2. Forest plots representing the risk of all-cause mortality after abbreviated DAPT vs. conventional DAPT in HBR vs. non-HBR patients.




Supplemental Figure 3. Forest plots representing the risk of cardiovascular mortality after 1- and 3-month abbreviated DAPT vs. conventional DAPT.




Supplemental Figure 4. Forest plots representing the risk of cardiovascular mortality after abbreviated DAPT vs. conventional DAPT in pre-specified subgroups.




Supplemental Figure 5. Forest plots representing the risk of cardiovascular mortality after abbreviated DAPT vs. conventional DAPT in HBR vs. non-HBR patients.




Supplemental Figure 6. Forest plots representing the risk of stroke after 1- and 3-month abbreviated DAPT vs. conventional DAPT.




Supplemental Figure 7. Forest plots representing the risk of stroke after abbreviated DAPT vs. conventional DAPT in pre-specified subgroups.




Supplemental Figure 8. Forest plots representing the risk of stroke after abbreviated DAPT vs. conventional DAPT in HBR vs. non-HBR patients.




Supplemental Figure 9. Forest plots representing the risk of non-fatal MI after 1- and 3-month abbreviated DAPT vs. conventional DAPT.




Supplemental Figure 10. Forest plots representing the risk of non-fatal MI after abbreviated DAPT vs. conventional DAPT in pre-specified subgroups.




Supplemental Figure 11. Forest plots representing the risk of non-fatal MI after abbreviated DAPT vs. conventional DAPT in HBR vs. non-HBR patients.




Supplemental Figure 12. Forest plots representing the risk of any revascularization after 1- and 3-month abbreviated DAPT vs. conventional DAPT.




Supplemental Figure 13. Forest plots representing the risk any revascularization after abbreviated DAPT vs. conventional DAPT in pre-specified subgroups.




Supplemental Figure 14. Forest plots representing the risk of any revascularization after abbreviated DAPT vs. conventional DAPT in HBR vs. non-HBR patients.




Supplemental Figure 15. Forest plots representing the risk of target vessel revascularization after 1- and 3-month abbreviated DAPT vs. conventional DAPT.




Supplemental Figure 16. Forest plots representing the risk target vessel revascularization after abbreviated DAPT vs. conventional DAPT in pre-specified subgroups.




Supplemental Figure 17. Forest plots representing the risk of target vessel revascularization after abbreviated DAPT vs. conventional DAPT in HBR vs. non-HBR patients.




Supplemental Figure 18. Forest plots representing the risk of in-stent thrombosis after 1- and 3-month abbreviated DAPT vs. conventional DAPT.




Supplemental Figure 19. Forest plots representing the risk in-stent thrombosis after abbreviated DAPT vs. conventional DAPT in pre-specified subgroups.




Supplemental Figure 20. Forest plots representing the risk of in-stent thrombosis after abbreviated DAPT vs. conventional DAPT in HBR vs. non-HBR patients.




Supplemental Figure 21. Forest plots representing the risk of MACE after 1- and 3-month abbreviated DAPT vs. conventional DAPT.



Supplemental Figure 22. Forest plots representing the risk MACE after abbreviated DAPT vs. conventional DAPT in pre-specified subgroups.



Supplemental Figure 23. Forest plots representing the risk of MACE after abbreviated DAPT vs. conventional DAPT in HBR vs. non-HBR patients.



Sensitivity Analysis

Supplemental Table 2. Sensitivity analysis using the leave-one-out method for high heterogeneity models (I2 >70%) to assess each study's contribution to the pooled estimates.


All-Cause Mortality					
Excluded study	Pooled RR (95% CI)	p-value	tau^2	tau	I^2
STOPDAPT-2 (Watanabe-2024)	0.8912 [0.8053; 0.9864]	0.0261	0.0000	0.0000	0.0%
MASTER-DAPT (Landi-2023)	0.9045 [0.8197; 0.9980]	0.0456	0.0000	0.0000	0.0%
STOPDAPT-3 (Natsuaki-2024)	0.8823 [0.8010; 0.9720]	0.0112	0.0000	0.0000	0.0%
RESET (Kim-2012)	0.8981 [0.8180; 0.9859]	0.0240	0.0000	0.0000	0.0%
TPASS (Hong-2023)	0.8942 [0.8142; 0.9821]	0.0195	0.0000	0.0000	0.0%
HOSTIDEA (Han-2023)	0.8966 [0.8162; 0.9850]	0.0230	0.0000	0.0000	0.0%
SMARTCHOICE (Choi-2022)	0.8884 [0.8072; 0.9779]	0.0156	0.0000	0.0000	0.0%
TWILIGHT (Mehran-2019)	0.9028 [0.8208; 0.9929]	0.0351	0.0000	0.0000	0.0%
GLOBAL LEADERS-GLASS Substudy (Franzone-2019)	0.9096 [0.8227; 1.0057]	0.0646	0.0000	0.0000	0.0%
OPTIMIZE (Feres-2013)	0.8929 [0.8116; 0.9824]	0.0201	0.0000	0.0000	0.0%
GLOBAL LEADERS (Vranckx-2018)	0.8995 [0.8063; 1.0034]	0.0575	0.0000	0.0000	0.0%
TICO (Kim-2020)	0.9008 [0.8199; 0.9896]	0.0294	0.0000	0.0000	0.0%
REDUCE (Kendhi-2021)	0.8866 [0.8070; 0.9740]	0.0121	0.0000	0.0000	0.0%
Cardiovascular Mortality					
Excluded study	Pooled RR (95% CI)	p-value	tau^2	tau	I^2
STOPDAPT-2 (Watanabe-2024)	0.8948 [0.7639; 1.0480]	0.1679	0.0000	0.0000	0.0%
MASTERDAPT (Landi-2023)	0.8825 [0.7537; 1.0332]	0.1201	0.0000	0.0000	0.0%
STOPDAPT-3 (Natsuaki-2024)	0.8410 [0.7145; 0.9900]	0.0375	0.0000	0.0000	0.0%
RESET (Kim-2012)	0.8845 [0.7628; 1.0255]	0.1038	0.0000	0.0000	0.0%
TPASS (Hong-2023)	0.8858 [0.7632; 1.0280]	0.1105	0.0000	0.0000	0.0%
HOSTIDEA (Han-2023)	0.8853 [0.7627; 1.0277]	0.1095	0.0000	0.0000	0.0%
SMARTCHOICE (Choi-2019)	0.8624 [0.7395; 1.0058]	0.0593	0.0000	0.0000	0.0%
TWILIGHT (Mehran-2019)	0.8996 [0.7710; 1.0496]	0.1788	0.0000	0.0000	0.0%
GLOBAL LEADERS - GLASS Substudy (Franzone-2019)	0.9103 [0.7701; 1.0760]	0.2708	0.0000	0.0000	0.0%

OPTIMIZE (Feres-2013)	0.8786 [0.7530; 1.0252]	0.1002	0.0000	0.0000	0.0%
REDUCE (Kendhi-2021)	0.8653 [0.7451; 1.0048]	0.0579	0.0000	0.0000	0.0%
Stroke					
Excluded study	Pooled RR (95% CI)	p-value	tau^2	tau	I^2
STOPDAPT-2 (Watanabe-2023)	0.9588 [0.7999; 1.1494]	0.6496	0.0000	0.0000	0.0%
STOPDAPT-3 (Natsuaki-2024)	0.9214 [0.7710; 1.1012]	0.3683	0.0000	0.0000	0.0%
MASTERDAPT (Landi-2023)	0.9746 [0.8176; 1.1618]	0.7742	0.0000	0.0000	0.0%
TICO (Kim-2020)	0.9407 [0.7920; 1.1175]	0.4867	0.0000	0.0000	0.0%
TPASS (Hong-2023)	0.9408 [0.7920; 1.1176]	0.4875	0.0000	0.0000	0.0%
HOSTIDEA (Han-2023)	0.9407 [0.7922; 1.1171]	0.4857	0.0000	0.0000	0.0%
SMARTCHOICE (Choi-2022)	0.9091 [0.7630; 1.0833]	0.2867	0.0000	0.0000	0.0%
TWILIGHT (Mehran-2019)	0.9033 [0.7600; 1.0734]	0.2480	0.0000	0.0000	0.0%
GLOBAL LEADERS - GLASS Substudy (Franzone-2019)	0.9197 [0.7642; 1.1068]	0.3755	0.0000	0.0000	0.4%
OPTIMIZE (Feres-2013)	0.9313 [0.7851; 1.1046]	0.4136	0.0000	0.0002	1.7%
GLOBAL LEADERS (Vranckx-2018)	0.9141 [0.7463; 1.1197]	0.3854	0.0000	0.0000	0.5%
Non-fatal MI					
Excluded study	Pooled RR (95% CI)	p-value	tau^2	tau	I^2
STOPDAPT-2 (Watanabe-2023)	0.9960 [0.8969; 1.1060]	0.9399	0.0000	0.0000	0.0%
STOPDAPT-3 (Natsuaki-2024)	0.9501 [0.8400; 1.0746]	0.4152	0.0066	0.0814	14.5%
MASTERDAPT (Landi-2023)	0.9428 [0.8315; 1.0689]	0.3575	0.0064	0.0799	12.9%
TICO (Kim-2020)	0.9778 [0.8626; 1.1083]	0.7251	0.0088	0.0936	18.6%
RESET (Kim-2012)	0.9734 [0.8538; 1.1097]	0.6865	0.0120	0.1094	22.6%
TPASS (Hong-2023)	0.9717 [0.8470; 1.1147]	0.6816	0.0150	0.1225	25.5%
HOSTIDEA (Han-2023)	0.9625 [0.8425; 1.0995]	0.5731	0.0124	0.1114	22.9%
SMARTCHOICE (Choi-2019)	0.9785 [0.8542; 1.1208]	0.7535	0.0131	0.1145	23.6%
TWILIGHT (Mehran-2019)	0.9649 [0.8334; 1.1171]	0.6323	0.0150	0.1226	25.4%
GLOBAL LEADERS - GLASS Substudy (Franzone-2019)	1.0058 [0.8843; 1.1440]	0.9301	0.0057	0.0758	9.3%
OPTIMIZE (Feres-2013)	0.9543 [0.8332; 1.0930]	0.4993	0.0117	0.1080	21.3%
GLOBAL LEADERS (Vranckx-2018)	0.9638 [0.8268; 1.1235]	0.6375	0.0151	0.1227	25.1%


REDCUE (Kendhi-2021)	0.9585 [0.8384; 1.0958]	0.5348	0.0119	0.1093	22.2%
Any Revascularization					
Excluded study	Pooled RR (95% CI)	p-value	tau^2	tau	I^2
STOPDAPT-2 (Watanabe-2023)	1.0552 [0.8571; 1.2989]	0.6127	0.0226	0.1502	44.9%
STOPDAPT-3 (Natsuaki-2024)	0.9544 [0.8794; 1.0359]	0.2643	0.0000	0.0000	0.0%
RESET (Kim-2012)	0.9725 [0.8830; 1.0710]	0.5709	0.0014	0.0368	38.7%
HOSTIDEA (Han-2023)	1.0343 [0.8883; 1.2044]	0.6639	0.0105	0.1024	42.2%
SMARTCHOICE (Choi-2022)	0.9546 [0.8778; 1.0382]	0.2782	0.0000	0.0024	34.0%
GLOBAL LEADERS (Vranckx-2018)	1.0645 [0.9050; 1.2522]	0.4503	0.0018	0.0429	25.9%
In-Stent Thrombosis					
Excluded study	Pooled RR (95% CI)	p-value	tau^2	tau	I^2
STOPDAPT-2 (Watanabe-2024)	1.0476 [0.8813; 1.2453]	0.5981	0.0000	0.0000	0.0%
STOPDAPT-3 (Natsuaki-2024)	1.0058 [0.8429; 1.2001]	0.9491	0.0000	0.0000	0.0%
MASTERDAPT (Landi-2023)	1.0254 [0.8599; 1.2228]	0.7799	0.0000	0.0000	0.0%
TICO (Kim-2020)	1.0283 [0.8652; 1.2222]	0.7513	0.0000	0.0000	0.0%
RESET (Kim-2012)	1.0397 [0.8755; 1.2348]	0.6569	0.0000	0.0000	0.0%
TPASS (Hong-2023)	1.0358 [0.8723; 1.2300]	0.6883	0.0000	0.0000	0.0%
HOSTIDEA (Han-2023)	1.0323 [0.8697; 1.2253]	0.7161	0.0000	0.0000	0.0%
SMARTCHOICE (Choi-2022)	0.9922 [0.8101; 1.2151]	0.9394	0.0000	0.0000	0.0%
TWILIGHT (Mehran-2019)	1.0588 [0.8873; 1.2634]	0.5264	0.0000	0.0000	0.0%
GLOBAL LEADERS - GLASS Substudy (Franzone-2019)	1.1035 [0.9168; 1.3284]	0.2977	0.0000	0.0000	0.0%
OPTIMIZE (Feres-2013)	1.0334 [0.8671; 1.2315]	0.7137	0.0000	0.0000	0.0%
GLOBAL LEADERS (Vranckx-2018)	1.0473 [0.8389; 1.3074]	0.6831	0.0144	0.1199	0.0%
REDUCE (Kendhi-2021)	1.0141 [0.8519; 1.2071]	0.8752	0.0000	0.0000	0.0%
MACE					
Excluded study	Pooled RR (95% CI)	p-value	tau^2	tau	I^2
STOPDAPT-2 (Watanabe-2024)	0.9384 [0.8319; 1.0586]	0.3010	0.0000	0.0000	0.0%
MASTERDAPT (Landi-2023)	0.9266 [0.8163; 1.0519]	0.2389	0.0000	0.0000	0.0%
TPASS (Hong-2023)	0.9427 [0.8440; 1.0531]	0.2965	0.0000	0.0000	0.0%

SMARTCHOICE (Choi-2022)	0.9127 [0.8121; 1.0259]	0.1258	0.0000	0.0000	0.0%
OPTIMIZE (Feres-2013)	0.9144 [0.8129; 1.0286]	0.1360	0.0000	0.0000	0.0%
TICO (Kim-2020)	0.9506 [0.8496; 1.0635]	0.3760	0.0000	0.0000	0.0%
REDUCE (Kendhi-2021)	0.9259 [0.8230; 1.0417]	0.2003	0.0000	0.0000	0.0%


Supplemental Figure 24. Bubble plot of meta-regression analysis evaluating the age of the overall population as a covariate in all-cause mortality outcome.




Supplemental Figure 25. Bubble plot of meta-regression analysis evaluating the male percentage as a covariate in all-cause mortality outcome.




Supplemental Figure 26. Bubble plot of meta-regression analysis evaluating diabetes as a covariate in all-cause mortality outcome.




Supplemental Figure 27. Bubble plot of meta-regression analysis evaluating hypertension as a covariate in all-cause mortality outcome.




Supplemental Figure 28. Comparison-adjusted funnel plots for included studies that report all-cause mortality.




Supplemental Figure 29. Comparison-adjusted funnel plots for included studies that report cardiovascular mortality.




Supplemental Figure 30. Comparison-adjusted funnel plots for included studies that report stroke.



Supplemental Figure 31. Comparison-adjusted funnel plots for included studies that report non-fatal MI.



Supplemental Figure 32. Comparison-adjusted funnel plots for included studies that report target vessel revascularization.



Supplemental Figure 33. Comparison-adjusted funnel plots for included studies that report in-stent restenosis.

